51
|
Hor K, Cripe L, Taylor M, Jefferies J, Mazur W, Benson D. P1.16 The heart in Duchenne muscular dystrophy: The Cincinnati experience. Neuromuscul Disord 2011. [DOI: 10.1016/j.nmd.2011.06.776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
52
|
Kukla M, Mazur W, Bułdak RJ, Zwirska-Korczala K. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis. Mol Med 2011; 17:1397-1410. [PMID: 21738955 PMCID: PMC3321801 DOI: 10.2119/molmed.2010.00105] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2010] [Accepted: 07/05/2011] [Indexed: 08/10/2023] Open
Abstract
Chronic hepatitis C (CHC) is generally a slowly progressive disease, but some factors associated with rapid progression have been identified. Steatosis, independently of its metabolic or viral origin, leads to liver injury and fibrosis. It is suggested that hepatitis C virus may contribute to a wide spectrum of metabolic disturbances-namely, steatosis, insulin resistance, increased prevalence of impaired glucose tolerance, type 2 diabetes mellitus and lipid metabolism abnormalities. Adipokines, which are produced mainly by adipose tissue, may influence the inflammatory response and insulin sensitivity and contribute to the development of metabolic abnormalities in CHC and also regulate fibrogenesis and angiogenesis. Visfatin was described as an adipokine with immunomodulating and proinflammatory properties that promotes B-cell maturation and enhances activation of leukocytes, synthesis of adhesion molecules and production of proinflammatory cytokines. Visfatin exerts insulin-mimetic effects, decreases plasma glucose levels and regulates cell energy balance. Chemerin stimulates chemotaxis of dendritic cells, macrophages and natural killer (NK) cells toward the site of inflammation. On the other hand, it inhibits synthesis of proinflammatory mediators and enhances adiponectin production, influences adipocyte differentiation and maturation and regulates glucose uptake in adipocytes. Vaspin expression in human adipose tissue seems to be a compensatory mechanism associated with obesity and insulin resistance. Vaspin suppresses leptin, tumor necrosis factor (TNF)-α and resistin expression. Leptin protects against liver steatosis but accelerates fibrosis progression and exacerbates the inflammatory process. In contrast, adiponectin exerts a hepatoprotective effect. In this report, data indicating a possible role of these adipokines in the pathogenesis of chronic hepatitis are summarized.
Collapse
|
53
|
Mazur W, Toljamo T, Ohlmeier S, Vuopala K, Nieminen P, Kobayashi H, Kinnula VL. Elevation of surfactant protein A in plasma and sputum in cigarette smokers. Eur Respir J 2011; 38:277-84. [PMID: 21273386 DOI: 10.1183/09031936.00110510] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Serum surfactant protein (SP)-A has been postulated to associate with pulmonary fibrosis, but its role in cigarette smoking-related lung diseases is undefined. SP-A levels in plasma and induced sputum in nonsmokers, smokers with respiratory symptoms (cough and/or phlegm) and symptom-free smokers were assessed using a validated EIA method. A total of 474 current smokers without any diseases or medications were enrolled and followed for 2 yrs with 111 of them succeeding in stopping. Plasma SP-A level was detectable in all subjects and elevated in smokers independently of the symptoms compared to nonsmokers (p = 0.001). After 2 yrs of follow-up, the SP-A level was higher in those who continued smoking compared to the quitters (p<0.001). Plasma SP-A levels were associated with age, smoking history and lung function. Sputum (n = 109) SP-A was nondetectable in most nonsmokers, whereas smoking and symptoms increased sputum SP-A highly significantly (p = 0.001). In conclusion, SP-A may be involved in pathogenesis of cigarette smoking-related lung diseases. Further studies are needed to elucidate the role of SP-A in chronic obstructive pulmonary disease.
Collapse
|
54
|
Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Szczygiel B, Berdowska A, Mazur W, Wozniak-Grygiel E, Kryczka W. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat 2010; 17:661-7. [PMID: 20002564 DOI: 10.1111/j.1365-2893.2009.01224.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Adipocytokine profile seems to play a distinct role in the pathogenesis of chronic hepatitis C (CHC). Chemerin and vaspin are recently described adipocytokines with various suggested functions and potential to modulate inflammatory response and insulin resistance (IR). We assessed chemerin, vaspin and leptin serum concentration and studied their association with IR laboratory and morphological features in patients with hepatitis C. The study included 40 patients with hepatitis C and 20 healthy volunteers, similar in age and body mass index (43.6 +/- 11.6 vs 40.9 +/- 11.8 years and 25.0 +/- 4.1 vs 23.9 +/- 3.3 kg/m(2), respectively). Patients had to have a normal lipid profile, and diabetes was an exclusion criteria. Serum chemerin and leptin levels and IR were significantly higher in patients with hepatitis C when compared to the controls (P = 0.02, P = 0.02 and P = 0.02, respectively), whereas vaspin level was significantly decreased (P = 0.01). Serum chemerin was negatively associated with necro-inflammatory grade (r = (-0.49), P = 0.01). The lowest levels of serum chemerin were found in patients with moderate/severe inflammation (P = 0.03). Serum leptin tended to be up-regulated in patients with minimal inflammatory activity. Serum vaspin was higher, although not significantly, when fibrosis was more advanced. IR was positively associated with fibrosis stage (r = 0.33, P = 0.03). Serum chemerin and leptin were related to each other (r = 0.45, P = 0.02).Our findings support a complex interaction between the analysed adipokines and pathogenesis of inflammatory process in CHC. The role of chemerin and vaspin in pathogenesis of inflammatory response should be further investigated.
Collapse
|
55
|
Bialkowska J, Mazur W, Slusarczyk J, Jablkowski M. Age-dependent, differentiated prevalence of anti-HAV and anti-HBc antibodies among patients with chronic hepatits C (CHC): New aspect of future vaccination perspectives against hepatitis A Virus. Int J Infect Dis 2010. [DOI: 10.1016/j.ijid.2010.02.2012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
56
|
Kukla M, Ciupińska-Kajor M, Kajor M, Wyleżoł M, Żwirska-Korczala K, Hartleb M, Berdowska A, Mazur W. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. POL J PATHOL 2010; 61:147-153. [PMID: 21225497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Abstract
BACKGROUND Visfatin has been identified as a new adipokine with proinflammatory and immunomodulating properties. It seems to interfere with immune and fibrogenic process in nonalcoholic fatty liver disease (NAFLD). The aim was to assess visfatin expression in the liver tissue and its association with biochemical parameters and morphological features in NAFLD patients. MATERIAL AND METHODS The study included 40 severely obese patients with NAFLD who underwent intraoperative wedge liver biopsy during a bariatric operation. Immunohistochemical assay was carried out with the use of a visfatin mice monoclonal antibody. RESULTS Visfatin expression in the liver was observed in all patients. The expression was significantly higher in patients with fibrosis (p = 0.036) and was positively correlated with the fibrosis stage (r = 0.52, p = 0.03). There was no difference between patient with nonalcoholic steatohepatitis (NASH) and simple steatosis (p = 0.54). Inflammatory activity and NAS (NAFLD Activity Score) score were not associated with visfatin expression. There was a tendency of more evident visfatin liver expression in morbidly obese patients with diabetes mellitus. CONCLUSION Our study showed a positive association between visfatin and the fibrosis stage in NAFLD. This observation suggests a potential role of this adipokine in the pathogenesis and progression of NAFLD. Visfatin expression does not seem to be associated with liver steatosis and inflammation.
Collapse
|
57
|
Braczkowska B, Kowalska M, Beniowski M, Zejda JE, Mazur W, Witor A. [Occupational exposure to HIV in health care workers, Silesia voivodeship]. Med Pr 2010; 61:315-322. [PMID: 20677431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023] Open
Abstract
BACKGROUND Occupational exposure to HIV is defined as a contact of health care workers with potentially infectious material. The risk of occupational transmission is not high (0.09-0.3%), but it increases in case of percutaneous injuries caused by tools contaminated with infected blood, deep needle stick or direct contact of an infected needle with artery or vein. MATERIAL AND METHODS The aim of the study was to determine the epidemiology of HIV infections among health care workers in the Silesian voivodeship, in the years 1999-2006 and the conditions of occupational exposure. Data on occupational exposure, collected by the Center for AIDS Diagnosis and Therapy in Chorzów, were analyzed. RESULTS During the study period, 789 cases of occupational exposure to HIV in the medical staff were documented. In the exposed group women predominated (78.9%). In the occupational group under study, nurses made 65% and physicians 17.5%. Needles were the most frequent (75.2%) source of exposure during injections and left hand fingers (thumb and index finger) were the major targets. Post-exposure prophylaxis with antiretroviral medications was introduced in about 60% of cases (499/789). No HIV transmission was registered. CONCLUSIONS Nurses run the highest risk of occupational exposure to HIV, usually related with injections. There is a need to continue education in postexposure prophylaxis addressed to medical staff. The development of a standard questionnaire and its practical use could be very useful in monitoring occupational exposure.
Collapse
|
58
|
Pelberg R, Mazur W, Kim EE. Cardiac CT Angiography Manual. J Nucl Med 2008. [DOI: 10.2967/jnumed.107.049643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
59
|
Wedemeyer H, Mazur W, Nevens F, Horsmans Y, Adler M, Blum H, Inglot M, Gerken G, Janczewska E, Roskams T, Desmet V, Renault J, Joos E, Coart E, Maertens G, De Winter H. 61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION. J Hepatol 2008. [DOI: 10.1016/s0168-8278(08)60063-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
60
|
Juszczyk J, Baka-Cwierz B, Beniowski M, Berak H, Bolewska B, Boroń-Kaczmarska A, Cianciara J, Cieśla A, Dziambor A, Gasiorowski J, Gietka A, Gliwińska E, Gładysz A, Gonciarz Z, Halota W, Horban A, Inglot M, Janas-Skulina U, Janczewska-Kazek E, Jaskowska J, Jurczyk K, Knysz B, Kryczka W, Kuydowicz J, Lakomy EA, Logiewa-Bazger B, Lyczak A, Mach T, Mazur W, Michalska Z, Modrzewska R, Nazzal K, Pabjan P, Piekarska A, Piszko P, Sikorska K, Szamotulska K, Sliwińska M, Swietek K, Tomasiewicz K, Topczewska-Staubach E, Trocha H, Wasilewski M, Wawrzynowicz-Syczewska M, Wrodycki W, Zarebska-Michaluk D, Zejc-Bajsarowicz M. [Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)]. PRZEGLAD EPIDEMIOLOGICZNY 2005; 59:651-60. [PMID: 16433307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
UNLABELLED We evaluated the efficacy and safety of peginterferon alfa-2a [40KD] (Peg-IFNalpha-2a) plus ribavirin in patients with chronic hepatitis C in an open-label programme in a routine clinical setting in Poland. Patients received Peg-IFNalpha-2a 180mg/week plus ribavirin 800-1200 mg/d for 48 weeks. Sustained virological response (SVR) was defined as undetectable HCV RNA (<50IU/mL) at the end of follow-up (week 72). 466 adults were enrolled. Most patients (87.3%) had genotype 1 infection. 440 subjects (94,4%) completed treatment. The overall SVR rate was 55.7%. A higher SVR rate was obtained in treatment-naïve patients (58.7%) than in relapsers (47.8%; p=0,048). SVR rates in genotype 1 and non-1 patients were 51.1% and 88.5%, respectively (p<0.001). There were significant higher SVR rates in patients with lower baseline fibrosis (p=0,01). There were no differences in SVRs by gender or viral load. Hemoglobin, leukocyte and neutrophil levels decreased significantly during treatment, but returned to baseline after the end of treatment. ALT levels decreased significantly during treatment in patients with and without an SVR. 38.4% of patients experienced adverse events like neutropenia, anemia, thrombocytopenia, and other. There was one death (severe thrombocytopenia). CONCLUSIONS The overall SVR achieved in this predominantly genotype 1 population was 55.7%. SVR rates were significantly higher in treatment-naïve patients, those with non-1 genotypes, and in patients with lower baseline fibrosis scores.
Collapse
|
61
|
Jonderko K, Krusiec-Swidergoł B, Mazur W, Kasicka-Jonderko A, Gonciarz M, Błońska-Fajfrowska B, Gonciarz Z. Effect of single-dose administration of recombinant interferon-alpha2b on gastric myoelectrical activity in patients with chronic hepatitis C. J Gastroenterol 2004; 39:1035-44. [PMID: 15580395 DOI: 10.1007/s00535-004-1441-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2003] [Accepted: 05/20/2004] [Indexed: 02/04/2023]
Abstract
BACKGROUND Upper abdominal complaints during interferon therapy may result from impaired gastric motility and/or evacuatory function. We examined the effect of acute administration of interferon on gastric myoelectrical activity (GMA) with the use of surface electrogastrography. METHODS The study population comprised 25 patients with chronic hepatitis C. All of them were naive to interferon. On 2 days, after a 25-min basal GMA registration, in group A (5 men, 7 women, aged 44.3 +/- 2.8 years) placebo or 5 million i.u. recombinant interferon alpha-2b (IFNA) was administered s.c. and the GMA was recorded in the interdigestive state for two periods (2 h and 4 h), separated by a 15-min break. In group B (7 men, 6 women, aged 44.7 +/- 3.9 years) placebo or 5 million i.u. IFNA was injected s.c. after the ingestion of a semiliquid test meal of 364 kcal. Subsequently, the postprandial GMA was recorded for two periods (2 h and 4 h), separated by a 15-min break. RESULTS A typical flu-like syndrome was observed in 91.7% of patients in group A, and in 92.3% of patients in group B, thus providing evidence of the pharmacodynamic efficiency of the IFNA administration. In the fasted state, IFNA brought about a negligible increase in the rhythmicity and power of the gastric slow waves. IFNA did not elicit any statistically significant effect on gastric slow-wave activity postprandially. CONCLUSIONS Acute administration of interferon does not involve any deterioration of GMA that could be linked to the previously reported upper abdominal symptoms in patients undergoing treatment with this drug.
Collapse
|
62
|
Mesjasz J, Wiecek A, Gonciarz Z, Mazur W, Kokot F. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?]. POLSKI MERKURIUSZ LEKARSKI : ORGAN POLSKIEGO TOWARZYSTWA LEKARSKIEGO 2004; 16:362-7. [PMID: 15517934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
UNLABELLED Haemodialysed patients are highly exposed to different virus infections namely hepatitis B (HBV) and C (HCV). Recently it was shown, that the use of recombinant human erythropoietin (rHuEPO) in haemodialysed patients with chronic renal failure (CRF) stimulates not only erythropoesis but also increases--in an indirect or direct manner--the humoral and cell--mediated immune defense. The aim of the present study was to determine the prevalence of HBV and HCV infection in haemodialysed patients with CRF and renal anaemia treated either with rHuEPO or with allogenic blood transfusions only. 32 patients with CRF and renal anaemia (haematocrit value below 28%) were included in this study at the early stage of the dialysis therapy (0 to 6 months from the first haemodialysis session). All patients were randomly allocated into two groups. The first one consisted of 15 haemodialysed patients treated with rHuEPO, the second group composed of 17 occasionally treated with blood transfusions (No-EPO group). In patients of both groups the following parameters were examined before (0) and after 3, 6, 9, 12 months of monitoring number of units blood transfused, hemoglobin concentration, serum levels of ferritin. Before the study (0) and after 6 and 12 months presence of antigen HBs (AgHBs), antibodies anti-HBc, anti-HBs, anti-HCV, DNA HBV and RNA HCV were examined. Before the study markers of HBV infection (DNA HBV and/or AgHBs and/or anti-HBc) were found in 46.7% of patients in EPO group and in 52.9% of patients in NO-EPO group respectively (NS). After six months of the study markers of HBV infection were present in 60% of patients in EPO group and in 76.5% of patients in No-EPO group (NS). After 12 months of dialysotherapy HBV infection markers were found in 66.7% patients in EPO group and in 76.5% of patients in No-EPO group (NS). Significantly higher prevalence of HBV infections were found after 6 and 12 months respectively in No-EPO group in comparison to the prestudy period (p < 0.05). At the beginning of the study markers of HCV infection (RNA HCV and/or anti-HCV) were present in 26.7% of patients in EPO group compared to 35.3% of patients in No-EPO group (NS). After 6 months of therapy markers of HCV infection were found in 26.7% of patients in EPO group and in 64.7% of patients in No-EPO group (p < 0.05). After 12 months of treatment markers of HCV infections were present in 40% of patients in EPO group and 76.5% of patients in No-EPO group (p < 0.05).ln patients of No-EPO group significantly higher prevalence of HCV infection ware found after 6 and 12 months of the follow-up compared to the prestudy period (p < 0.05 and p < 0.01 respectively). CONCLUSIONS Treatment of renal anaemia with rHuEPO contributes to the significant decrease in prevalence of HCV infection. Decrease of prevalence of HCV infection in haemodialysed patients with chronic renal failure treated with rHuEPO seems to be predominantly a result of the complete cessation of allogenic blood transfusion. Blood transfusions seem not to be the main cause of HBV transmission in haemodialysed patients.
Collapse
|
63
|
Mazur W, Gonciarz M, Kajdy M, Mazurek U, Jurzak M, Wilczok T, Gonciarz Z. Blood serum glutathione alpha s-transferase (alpha GST) activity during antiviral therapy in patients with chronic hepatitis C. Med Sci Monit 2003; 9 Suppl 3:44-8. [PMID: 15156612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Glutathione transferases (GST) belong to enzymes involved primarily in the processes of detoxification of exo- and endogenous substances. Immunohistochemical studies have demonstrated that alpha-GST present in the liver is localized exclusively in hepatocytes. The activity of alpha-GST is reported to reflect interstitial liver damage better than that of aminotransferases, especially in patients with autoimmune hepatitis, and, according to some authors, also in patients with chronic hepatitis C. The GST system has also been proposed to be indirectly involved in hepatocellular damage due to hepatitis C virus (HCV) infection. THE AIM OF THE STUDY Was to assess the utility of alpha-GST as an accessory marker in monitoring antiviral therapy in patients with chronic hepatitis C. MATERIAL/METHODS 21 patients (12 males and 9 females) with chronic HCV infections were evaluated. The diagnosis was based on clinical presentation and detection of anti-HCV, as well as the presence of HCV-RNA in blood serum detected by PCR. Fifteen patients (group I) were treated with interferon alpha-2b (IFN alpha-2b) at 3 MU s.c. doses administered three times a week (tiw) and ribavirin at 0.8 do 1.2 g/day doses, whereas 6 remaining patients (Group II) were treated with IFN alpha-2b alone at 5 MU s.c. tiw doses. The activity of alpha GST was determined with ELISA before and after 6 months of treatment, together with assessment of HCV-RNA viremia determining the decision concerning continuation of the therapy. RESULTS The results are presented in Table 1 as mean values +/- SD. *p, 0.05. CONCLUSIONS Combined antiviral treatment with IFN alpha-2b and ribavirin, and IFN alpha-2b monotherapy reduce blood serum alpha-GST activity in patients with chronic hepatitis C. alpha-GST is less useful as a liver damage parameter than ALT in monitoring of antiviral treatment.
Collapse
|
64
|
Mazur W, Gonciarz M, Mazurek U, Jurzak M, Wilczok T, Gonciarz Z. Hepatitis C virus RNA level changes in sera during different regimens of treatment in patients with chronic hepatitis C. Med Sci Monit 2003; 9 Suppl 3:39-43. [PMID: 15156611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Interferon alfa-2b (IFN) has been shown to be effective for chronic hepatitis C infection, but treatment efficacy is still limited. Sustained response after interferon alfa monotherapy is achieved in about 15-25%. Great efforts are made to identify more effective forms of therapy. Some of them include modifications of dosage of antiviral drugs, duration of the therapy and more optimal selection of patients for the treatment. Several virus- and host-related predictive factors for response to antiviral treatment have been proposed. One of the key predictive factors of sustained response to therapy are the pretreatment levels of viremia as well as the dynamics of initial changes of HCV-RNA levels assessed during antiviral therapy. AIM The aim of our study was to compare changes of HCV-RNA viremia in patients with chronic hepatitis C during different regimens of antiviral treatment. MATERIAL/METHODS 21 patients chronically infected with HCV (anti-HCV positive, HCV-RNA positive by PCR) were enrolled in the study. 11 patients (Group I) were treated with interferon alfa-2b (IFN-alpha 2b) at 3 MU tiw doses administered subcutaneously for 12 months. 10 patients (Group II) received 3 MU of IFN-alpha 2b daily during the first month and later the treatment was continued with the same dosage tiw for the next 11 months. The response to the treatment was assessed according to the generally accepted criteria after 6-month follow-up. The initial decline of HCV-RNA after 4 weeks of therapy was assessed. RESULTS Results are presented in the Table. HCV-RNA expressed in copy/ml. CONCLUSION The initial decline of HCV-RNA level during the first 4 weeks of antiviral therapy with interferon correlates with the final response to the treatment. The greater decline of viremia was observed in the group of patients treated with the 'induction' variant of treatment.
Collapse
|
65
|
Konturek SJ, Gonciarz M, Gonciarz Z, Bielanski W, Mazur W, Mularczyk A, Konturek PC, Goetze JP, Rehfeld JF. Progastrin and its products from patients with chronic viral hepatitis and liver cirrhosis. Scand J Gastroenterol 2003; 38:643-7. [PMID: 12825873 DOI: 10.1080/00365520310002472] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Gastrin and its precursor, progastrin, are synthesized in the stomach, particularly when infected with Helicobacter pylori, and they are metabolized, at least in part, in the liver. However, little is known about their levels in various hepatic diseases. METHODS This study was carried out on 147 patients including chronic hepatitis B (n = 35), hepatitis C (n = 52) and liver cirrhosis (n = 60) of class A (n = 38), class B (n = 15) and class C (n = 7) (Child-Pugh classification) and age- and sex-matched healthy controls (n = 65). The diagnosis of chronic hepatitis was confirmed by liver biopsy in all patients, whereas the diagnosis of liver cirrhosis was based on clinical and laboratory findings. Liver biopsy was done in 38 out of 60 patients. Blood samples were collected under basal conditions and separated plasma samples were kept frozen at -70 degrees C until radioimmunoassay of progastrin and its products, including bioactive amidated gastrins. RESULTS Median (range) plasma concentrations of total progastrin product and amidated gastrin in control subjects were 147.5 (73-345) pM and 33 (15-65), respectively. These concentrations in hepatitis B and C were not significantly different from those in controls. In cirrhosis (classes A, B and C), the concentrations of the progastrin and of gastrin were significantly (P < 0.05) higher than in controls reaching, respectively, 253.5 (135-683 pM) and 47.5 (17-385) pM. Both progastrin and gastrin levels were significantly higher in H. pylori-positive than in negative cirrhotic patients. Antibodies against H. pylori were present in about 50% of controls, 68% of hepatitis B, 57% of hepatitis C and in 83% in cirrhosis patients. The difference in H. pylori prevalence between cirrhosis and controls was statistically significant. CONCLUSIONS Plasma levels of progastrin and gastrin are significantly increased in cirrhotic patients and this could be attributed to reduced metabolism of these peptides in liver cirrhosis and to their increased release due to H. pylori infection rate in this disease.
Collapse
|
66
|
Musialik J, Michałkiewicz J, Petelenz M, Mazurek U, Mazur W, Madaliński K, Gonciarz Z. Reduction of CD45RA Isoform Expression and Decrease in CD4 and CD8 Receptor Density in Lymphocytes of Patients with Primary Biliary Cirrhosis. Scand J Gastroenterol 2003; 38:421-426. [PMID: 28240143 DOI: 10.1080/00365520310000843] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The immunological background of primary biliary cirrhosis (PBC) remains largely obscure. METHODS Using double colour flow cytometry, we estimated the distribution of functionally different lymphocyte subpopulations in the peripheral blood of 25 PBC patients and 18 controls. We examined: 1) the expression of CD3, CD4, CD8, CD 19 and CD56 surface receptors, 2) the distribution of lymphocyte subsets bearing 'naive' (CD45RA+) and 'memory' (CD45RO+) phenotypes in both CD4+ and CD8+ cell populations, 3) the expression of an early activation marker (CD69), 4) the distribution of C1.7 mAb binding cytotoxic effectors in CD3+, CD8+ and CD56+ cells. The surface marker expression was evaluated in terms of percentage of positive cells and receptor density. RESULTS We found: 1) a decrease in the percentage of total CD3+ and CD4+ cells, an unchanged proportion of CD8+ cells but elevated proportion of CD 19+ cells and NK lymphocytes; 2) a reduction in the percentage of 'naive' CD4+ but normal proportion of 'naive' CD8+ as well as CD4+ and CD8+ 'memory' cell subsets; 3) a decrease in the density of CD4 and CD8 receptors in the subsets of 'naive' and 'memory' T cells, 4) an increase in the percentage of CD69 receptor bearing T cells but unchanged proportion of C1.7 mAb. CONCLUSIONS It is concluded that the reduction in number of 'suppressor-inducer-like 'naive' CD4+ T-cell subsets in association with the decrease in fluorescence intensity for CD4 and CD8 may significantly contribute to the mechanisms that could account for a development of PBC.
Collapse
|
67
|
Musialik J, Michalkiewicz J, Petelenz M, Mazurek U, Mazur W, Madaliński K, Gonciarz Z. Reduction of CD45RA isoform expression and decrease in CD4 and CD8 receptor density in lymphocytes of patients with primary biliary cirrhosis. Scand J Gastroenterol 2003; 38:421-6. [PMID: 12739715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
BACKGROUND The immunological background of primary biliary cirrhosis (PBC) remains largely obscure. METHODS Using double colour flow cytometry, we estimated the distribution of functionally different lymphocyte subpopulations in the peripheral blood of 25 PBC patients and 18 controls. We examined: 1) the expression of CD3, CD4, CD8, CD19 and CD56 surface receptors, 2) the distribution of lymphocyte subsets bearing 'naive' (CD45RA+) and 'memory' (CD45RO+) phenotypes in both CD4+ and CD8+ cell populations, 3) the expression of an early activation marker (CD69), 4) the distribution of C1.7 mAb binding cytotoxic effectors in CD3+, CD8+ and CD56+ cells. The surface marker expression was evaluated in terms of percentage of positive cells and receptor density. RESULTS We found: 1) a decrease in the percentage of total CD3+ and CD4+ cells, an unchanged proportion of CD8+ cells but elevated proportion of CD19+ cells and NK lymphocytes; 2) a reduction in the percentage of 'naive' CD4+ but normal proportion of 'naive' CD8+ as well as CD4+ and CD8+ 'memory' cell subsets; 3) a decrease in the density of CD4 and CD8 receptors in the subsets of 'naive' and 'memory' T cells, 4) an increase in the percentage of CD69 receptor bearing T cells but unchanged proportion of C1.7 mAb. CONCLUSIONS It is concluded that the reduction in number of 'suppressor-inducer-like 'naive' CD4+ T-cell subsets in association with the decrease in fluorescence intensity for CD4 and CD8 may significantly contribute to the mechanisms that could account for a development of PBC.
Collapse
|
68
|
Mazur W. [Alcoholic and nonalcoholic liver steatosis]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ 2003; 105 Suppl:425-8. [PMID: 12412281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
|
69
|
Mazur W, Król F, Cianciara J, Nazzal K, Gładysz A, Juszczyk J, Bolewska B, Adamek J, Czajka B, Swietek K, Kryczka W, Gonciarz Z. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection. Med Sci Monit 2002; 8:CR257-62. [PMID: 11951067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/24/2023] Open
Abstract
BACKGROUND Patients with on-going HBV viral replication often present with clinical features of active chronic hepatitis. Until the recent introduction of nucleoside analogues, interferon-alpha was the only approved drug for these patients. One of the former drugs, lamivudine, has been shown in clinical trials in the US and Asia to effectively inhibit the viral polymerase of HBV. Our study was undertaken to assess the efficacy and safety of lamivudine therapy in Polish patients with chronic hepatitis B. MATERIAL/METHODS Forty-five patients with chronic hepatitis B (HBeAg positive, anti-e negative, HBV-DNA positive by hybridization assay) were enrolled in the study. The patients received 100mg of lamivudine orally, once daily for 12 months. They returned for routine clinical and laboratory control every two weeks during the first months of treatment, and later at 3-month intervals while receiving lamivudine. RESULTS At the end of treatment, serum HBeAg was not detected in 21 patients (48.8%), and anti-HBe appeared in the serum of 19 patients. 37.2% of the patients in the study group showed sustained suppression of serum HBV DNA at the end of treatment. Lamivudine therapy was well tolerated, with the rate of occurrence of adverse events similar to that observed in other clinical studies. CONCLUSIONS 12-month lamivudine therapy in this Polish population of patients with chronic hepatitis B induced a high rate of HBeAg seroconversion, accompanied by reduction of HBV-DNA and the normalization of alanine aminotransferase activities.
Collapse
|
70
|
Nurmi T, Mazur W, Heinonen S, Kokkonen J, Adlercreutz H. Isoflavone content of the soy based supplements. J Pharm Biomed Anal 2002; 28:1-11. [PMID: 11861103 DOI: 10.1016/s0731-7085(01)00612-4] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
A large number of soy isoflavone products with indications of possible health effects are available on the market. Fifteen different soy based products were analyzed using high performance liquid chromatography (HPLC) with coulometric electrode array detector to determine the total amount of isoflavones in aglycones after the hydrolysis and identify the different forms of the isoflavone conjugates. The aim of the study was to evaluate how well the isoflavone content data supplied by the producers correspond to our analysis results. Only one product contained isoflavones measured in aglycones the same amount as was the value given by the producer. The total amount of the isoflavones in aglycones ranged from 0.121 to 201 mg/g. Measured amounts of isoflavones in aglycones after the hydrolysis were in general lower than the values in the product labels. Product data were often confusing and the concrete amount of isoflavones was difficult to find out.
Collapse
|
71
|
Mazurek U, Wilczok T, Mazur W, Bednarek I, Strzałka B, Jurzak M, Laskowska-Lepiarczyk E, Gonciarz Z. Distribution of hepatitis C virus RNA in whole blood of patients with HCV infection and HBV-HCV coinfection. Med Sci Monit 2002; 8:CR125-30. [PMID: 11859286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
BACKGROUND Although HCV and HBV are essentially hepatoptropic, several lines of evidence suggest that these viruses can infect other cells, also PBMC in most patients with chronic HCV. MATERIAL/METHODS The presence of HBV DNA and HCV-RNA was determined by a polymerase chain reaction (multiplex PCR and RT-PCR - nested PCR) in a group of patients with chronic liver disease. HCV-RNA was investigated in serum, plasma and peripheral blood mononuclear cells (PBMC) while HBV-DNA only in serum or plasma. RESULTS Among 374 patients tested, HCV-RNA was detected in the venous blood of 208 patients; HCV RNA alone was detected in 154 patients and 54 patients were co-infected by HCV and HBV. HBV-DNA was found in 128 of 374 patients, while infection by HBV only was found in 74 patients. It was also shown that in the presence of HBV the replication ability of HCV is lower (p=0.085, Goodman-Kruskal Gamma = 0.561 and YuleQ = 0.5610). CONCLUSIONS Since coexistence of HBV and HCV is not a rare case, diagnostics of hepatitis cannot be limited to detection of one type of the virus only. Misinterpretation of the virus type that caused the infection may lead to serious complications, especially in those cases when interferone is used for treatment.
Collapse
|
72
|
Juszczyk J, Bolewska B, Flieger J, Swietek K, Adamek B, Biskupska-Karasińska M, Dziambor AP, Boroń-Kaczmarska A, Wawrzynowicz-Syczewska M, Cianciara J, Kozłowska J, Daniluk J, Słomka M, Dudziak M, Zaborowski P, Gładysz A, Piszko P, Gonciarz Z, Mazur W, Machniak M, Kryczka W, Zarebska-Michaluk D, Trocha H, Witczak-Malinowska K, Lakomy E, Kuydowicz J, Niwicka-Michałowska A. [Effectiveness of antiviral treatment of patients with chronic hepatitis C (a Polish multicenter study)]. POLSKI MERKURIUSZ LEKARSKI : ORGAN POLSKIEGO TOWARZYSTWA LEKARSKIEGO 2001; 11:340-3. [PMID: 11770315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/17/2023]
Abstract
Interferon alpha (INF) is routine treatment in patients with chronic hepatitis C. Many controlled investigations were evaluated to establish the optimal schedule of treatment with sustained virological and biochemical response. Recently, multicentre meta-analyses suggest that combination therapy (INF + Ribavirin) was more effective than treatment with interferon alone. The aim of this study was to compare the efficacy of four schedules of antiviral treatment in 445 patients with chronic hepatitis C. Combination therapy (INF + Ribavirin) given for 6 mo. and monotherapy (INF) for 18 mo. were more effective than interferon alone given for 6 mo. Treatment with INF alone for 6 mo. was demonstrated to be insufficient.
Collapse
|
73
|
Kałuza GL, Raizner AE, Mazur W, Schulz DG, Zymek PT, Nguyen-Ho P, Tio FO, Fajardo LF, Ali NM. Dose-response study of intracoronary beta-radiation with 32P in balloon- and stent-injured coronary arteries in swine. CARDIOVASCULAR RADIATION MEDICINE 2001; 2:225-30. [PMID: 12160764 DOI: 10.1016/s1522-1865(01)00089-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE A dose-response study was performed in swine to investigate the vascular effects of 32P over a broad range of doses in order to define the therapeutic window of intracoronary radiotherapy (ICR) with 32P. METHODS AND MATERIALS A total of 131 porcine arteries were subjected to balloon injury or stenting followed by 0-36 Gy of ICR from a centered 32P source wire to 1 mm beyond lumen surface or a sham ICR procedure. Animals were euthanized at 4 weeks, and vessels were harvested for histomorphometry. RESULTS In the balloon-injured arteries, doses of 7 and 9 Gy did not impact restenosis. At doses of 14-36 Gy, neointima was markedly reduced, with mild dilatation at the highest dose, 36 Gy. In the stent-injured arteries, the lowest dose of 9 Gy failed to reduce neointimal growth, while 14-26 Gy showed the most favorable response. CONCLUSIONS ICR with 32P features a broad therapeutic window. Doses of 14-26 Gy to 1 mm beyond lumen surface provided an optimal combination of efficacy and safety. Doses of 7 and 9 Gy were generally ineffective, suggesting a minimum threshold for ICR with 32P to effectively inhibit restenosis.
Collapse
|
74
|
Abstract
The long-term prognosis of patients with ischemic cardiomyopathy is highly variable, depending on the extent of myocardial viability and the success and completeness of the revascularization techniques used. Other important factors include left ventricular function, extent of coronary artery disease (CAD), and patient age. Chronic left ventricular dysfunction in ischemic cardiomyopathy is the result of a mixture of scarred as well as hibernating myocardium. In fact, most patients have both scarring and hibernation in different regions. Transmural biopsies of dysfunctional segments reveals that recovery of function is inversely proportional to the extent of fibrosis and that endocardial fibrosis extending over 30% of the myocardial thickness precludes recovery of function.Nagueh et al. [1] evaluated the relation of contractile reserve and thallium uptake in hibernating myocardium to myocardial structure in humans. The authors found that segments with postoperative functional recovery had more wall thickening at low-dose dobutamine echocardiography (DE), higher thallium uptake, and less fibrosis (2.0 vs 28%) than those segments without recovery. Also, segments with viability on DE had less fibrosis, less vimentin and fibronectin, more glycogen, and higher thallium uptake, than those segments without viability. Importantly, segments viable by single-photon emission computed tomography (SPECT) and DE had significantly less fibrosis (1%) than those viable by only one of the two techniques. In this review, we discuss recent developments in the detection of myocardial viability, including echocardiography, nuclear cardiac imaging, magnetic resonance imaging (MRI), and other techniques.
Collapse
|
75
|
Stetson SJ, Perez-Verdia A, Mazur W, Farmer JA, Koerner MM, Weilbaecher DG, Entman ML, Quiñones MA, Noon GP, Torre-Amione G. Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation 2001; 104:676-81. [PMID: 11489774 DOI: 10.1161/hc3101.093765] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The mechanisms that contribute to cardiac allograft hypertrophy are not known; however, the rapid progression and severity of hypertrophy suggest that nonhemodynamic factors may play a contributory role. Tumor necrosis factor-alpha (TNF-alpha) is a cytokine produced in cardiac allografts and capable of producing hypertrophy and fibrosis; therefore, we suggest that TNF-alpha may play a contributory role. Accordingly, the aims of our study were to define the role of systemic hypertension in the development of hypertrophy, characterize the histological determinants of hypertrophy, and characterize the expression of myocardial TNF-alpha after heart transplantation. METHODS AND RESULTS To separate the effect of hypertension from immune injury in the development of cardiac allograft hypertrophy, we measured the gain in left ventricular mass by 2D echocardiography in heart transplant recipients and lung transplant recipients who developed similar rates of systemic hypertension. The gain in left ventricular mass was 73% in heart transplant recipients and 7% in lung transplant recipients (P<0.0001). By comparing myocardial samples obtained during the first week after transplant and at 1 year, we found that there was a significant increase in total collagen content (P<0.0001), collagen I (P<0.0001), collagen III (P<0.0001), and myocyte size (P<0.0001). These changes were associated with persistent myocardial TNF-alpha expression. CONCLUSIONS We suggest that the contribution of hypertension to cardiac allograft hypertrophy is minimal and that persistent intracardiac expression of TNF-alpha may contribute to the development of cardiac allograft hypertrophy.
Collapse
|